Hikma Pharmaceuticals receives warning letter from FDA

24th Oct 2014 07:38

Pharmaceuticals group Hikma received a warning letter from the US Food and Drug Administration overnight relating to its manufacturing facility in Portugal. The agency raised issues related to investigations and environmental monitoring at the facility.The warning is not expected to impact the manufacture or distribution of products from that site nor the company's financial guidance for this year, Hikma said in a statement.